Cargando…

Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles

BACKGROUND: Cholangiocarcinoma (CCA) is a malignancy of the cholangiocytes. One of the major issues regarding treatment for CCA patients is the development of chemotherapeutic resistance. Recently, the association of intratumoral bacteria with chemotherapeutic response has been reported in many canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sitthirak, Sirinya, Suksawat, Manida, Phetcharaburanin, Jutarop, Wangwiwatsin, Arporn, Klanrit, Poramate, Namwat, Nisana, Khuntikeo, Narong, Titapun, Attapol, Jarearnrat, Apiwat, Sangkhamanon, Sakkarn, Loilome, Watcharin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390323/
https://www.ncbi.nlm.nih.gov/pubmed/35990899
http://dx.doi.org/10.7717/peerj.13876
_version_ 1784770628811751424
author Sitthirak, Sirinya
Suksawat, Manida
Phetcharaburanin, Jutarop
Wangwiwatsin, Arporn
Klanrit, Poramate
Namwat, Nisana
Khuntikeo, Narong
Titapun, Attapol
Jarearnrat, Apiwat
Sangkhamanon, Sakkarn
Loilome, Watcharin
author_facet Sitthirak, Sirinya
Suksawat, Manida
Phetcharaburanin, Jutarop
Wangwiwatsin, Arporn
Klanrit, Poramate
Namwat, Nisana
Khuntikeo, Narong
Titapun, Attapol
Jarearnrat, Apiwat
Sangkhamanon, Sakkarn
Loilome, Watcharin
author_sort Sitthirak, Sirinya
collection PubMed
description BACKGROUND: Cholangiocarcinoma (CCA) is a malignancy of the cholangiocytes. One of the major issues regarding treatment for CCA patients is the development of chemotherapeutic resistance. Recently, the association of intratumoral bacteria with chemotherapeutic response has been reported in many cancer types. METHOD: In the present study, we aimed to investigate the association between the intratumoral microbiome and its function on gemcitabine and cisplatin response in CCA tissues using 16S rRNA sequencing and 1H NMR spectroscopic analysis. RESULT: The results of 16S rRNA sequencing demonstrated that Gammaproteobacteria were significantly higher in both gemcitabine- and cisplatin-resistance groups compared to sensitive groups. In addition, intratumoral microbial diversity and abundance were significantly different compared between gemcitabine-resistant and sensitive groups. Furthermore, the metabolic phenotype of the low dose gemcitabine-resistant group significantly differed from that of low dose gemcitabine-sensitive group. Increased levels of acetylcholine, adenine, carnitine and inosine were observed in the low dose gemcitabine-resistant group, while the levels of acetylcholine, alpha-D-glucose and carnitine increased in the low dose cisplatin-resistant group. We further performed the intergrative microbiome-metabolome analysis and revealed a correlation between the intratumoral bacterial and metabolic profiles which reflect the chemotherapeutics resistance pattern in CCA patients. CONCLUSION: Our results demonstrated insights into the disruption of the microbiome and metabolome in the progression of chemotherapeutic resistance. The altered microbiome-metabolome fingerprints could be used as predictive markers for drug responses potentially resulting in the development of an appropriate chemotherapeutic drug treatment plan for individual CCA patients.
format Online
Article
Text
id pubmed-9390323
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-93903232022-08-20 Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles Sitthirak, Sirinya Suksawat, Manida Phetcharaburanin, Jutarop Wangwiwatsin, Arporn Klanrit, Poramate Namwat, Nisana Khuntikeo, Narong Titapun, Attapol Jarearnrat, Apiwat Sangkhamanon, Sakkarn Loilome, Watcharin PeerJ Biochemistry BACKGROUND: Cholangiocarcinoma (CCA) is a malignancy of the cholangiocytes. One of the major issues regarding treatment for CCA patients is the development of chemotherapeutic resistance. Recently, the association of intratumoral bacteria with chemotherapeutic response has been reported in many cancer types. METHOD: In the present study, we aimed to investigate the association between the intratumoral microbiome and its function on gemcitabine and cisplatin response in CCA tissues using 16S rRNA sequencing and 1H NMR spectroscopic analysis. RESULT: The results of 16S rRNA sequencing demonstrated that Gammaproteobacteria were significantly higher in both gemcitabine- and cisplatin-resistance groups compared to sensitive groups. In addition, intratumoral microbial diversity and abundance were significantly different compared between gemcitabine-resistant and sensitive groups. Furthermore, the metabolic phenotype of the low dose gemcitabine-resistant group significantly differed from that of low dose gemcitabine-sensitive group. Increased levels of acetylcholine, adenine, carnitine and inosine were observed in the low dose gemcitabine-resistant group, while the levels of acetylcholine, alpha-D-glucose and carnitine increased in the low dose cisplatin-resistant group. We further performed the intergrative microbiome-metabolome analysis and revealed a correlation between the intratumoral bacterial and metabolic profiles which reflect the chemotherapeutics resistance pattern in CCA patients. CONCLUSION: Our results demonstrated insights into the disruption of the microbiome and metabolome in the progression of chemotherapeutic resistance. The altered microbiome-metabolome fingerprints could be used as predictive markers for drug responses potentially resulting in the development of an appropriate chemotherapeutic drug treatment plan for individual CCA patients. PeerJ Inc. 2022-08-16 /pmc/articles/PMC9390323/ /pubmed/35990899 http://dx.doi.org/10.7717/peerj.13876 Text en ©2022 Sitthirak et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Biochemistry
Sitthirak, Sirinya
Suksawat, Manida
Phetcharaburanin, Jutarop
Wangwiwatsin, Arporn
Klanrit, Poramate
Namwat, Nisana
Khuntikeo, Narong
Titapun, Attapol
Jarearnrat, Apiwat
Sangkhamanon, Sakkarn
Loilome, Watcharin
Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles
title Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles
title_full Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles
title_fullStr Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles
title_full_unstemmed Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles
title_short Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles
title_sort chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles
topic Biochemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390323/
https://www.ncbi.nlm.nih.gov/pubmed/35990899
http://dx.doi.org/10.7717/peerj.13876
work_keys_str_mv AT sitthiraksirinya chemotherapeuticresistantcholangiocarcinomadisplayeddistinctintratumoralmicrobialcompositionandmetabolicprofiles
AT suksawatmanida chemotherapeuticresistantcholangiocarcinomadisplayeddistinctintratumoralmicrobialcompositionandmetabolicprofiles
AT phetcharaburaninjutarop chemotherapeuticresistantcholangiocarcinomadisplayeddistinctintratumoralmicrobialcompositionandmetabolicprofiles
AT wangwiwatsinarporn chemotherapeuticresistantcholangiocarcinomadisplayeddistinctintratumoralmicrobialcompositionandmetabolicprofiles
AT klanritporamate chemotherapeuticresistantcholangiocarcinomadisplayeddistinctintratumoralmicrobialcompositionandmetabolicprofiles
AT namwatnisana chemotherapeuticresistantcholangiocarcinomadisplayeddistinctintratumoralmicrobialcompositionandmetabolicprofiles
AT khuntikeonarong chemotherapeuticresistantcholangiocarcinomadisplayeddistinctintratumoralmicrobialcompositionandmetabolicprofiles
AT titapunattapol chemotherapeuticresistantcholangiocarcinomadisplayeddistinctintratumoralmicrobialcompositionandmetabolicprofiles
AT jarearnratapiwat chemotherapeuticresistantcholangiocarcinomadisplayeddistinctintratumoralmicrobialcompositionandmetabolicprofiles
AT sangkhamanonsakkarn chemotherapeuticresistantcholangiocarcinomadisplayeddistinctintratumoralmicrobialcompositionandmetabolicprofiles
AT loilomewatcharin chemotherapeuticresistantcholangiocarcinomadisplayeddistinctintratumoralmicrobialcompositionandmetabolicprofiles